Drugs / FT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05858983 | Nov 2022 → Nov 2025 overdue | RPE65-related recessive retinopathy | Frontera Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-09-21 | Frontera Therapeutics | Regulatory Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001 fronteratherapeutics.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-05 | Frontera Therapeutics | Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment fronteratherapeutics.com ↗ |
| 2023-01-06 | Frontera Therapeutics | Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2 fronteratherapeutics.com ↗ |
| 2022-09-21 | Frontera Therapeutics | Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001 fronteratherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05858983 ↗ |
| Route | Other | “Administered Via Subretinal Injection” NCT05858983 ↗ |